SEATTLE, Jan 9 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP (http://www.hbsslaw.com/cellcyte.htm) today announced it is investigating the business practices of CellCyte (OTC Bulletin Board: CCYG) for potential violations of securities laws.
The investigation comes after CellCyte's shares plunged 55 percent after news reports detailed alleged discrepancies in CellCyte CEO Gary Reys' educational and professional credentials.
CellCyte's stock dropped after the company made changes to its Web site concerning Reys' claims to have attended University of Washington and to be a certified public accountant. Media reports also call into question other claims made by Reys concerning his role in other business ventures.
According to published media reports, the changes were prompted by calls from Seattle media questioning the veracity of Reys' claims.
If you are an investor in CellCyte, have information concerning this investigation or if you have any questions concerning CellCyte's actions, please contact plaintiff's counsel at 206-623-7292 or e-mail the law firm at firstname.lastname@example.org. You can view additional materials on this investigation at http://www.hbsslaw.com/cellcyte.htm.
Hagens Berman Sobol Shapiro, a law firm with offices in Seattle, San
Francisco, Los Angeles, Boston, Chicago and Phoenix, is active in major
litigations pending in federal and state courts throughout the United
States and has taken a leading role in many important actions on behalf of
defrauded investors, consumers, and companies, as well as victims of human
rights violations. The Hagens Berman Web site (http://www.hbsslaw.com) has
more information about the firm.
Contact: Hagens Berman Sobol Shapiro LLP
|SOURCE Hagens Berman Sobol Shapiro LLP|
Copyright©2008 PR Newswire.
All rights reserved